Emerging ADC Targets Beyond HER2 and CD30
Antibody Drug Conjugates (ADCs) have historically focused on well-known targets such as HER2 and CD30, but the Antibody Drug Conjugate Market is now witnessing a shift toward emerging antigens that offer novel therapeutic avenues. This trend is expanding the potential utility of ADCs, especially in treating cancers that are refractory to conventional treatments or lack established biomarkers.
Targets such as TROP2, LIV-1, and B7-H3 are gaining traction due to their overexpression in various solid tumors and limited expression in healthy tissues. TROP2-targeting ADCs, for instance, have shown promise in breast, lung, and pancreatic cancers. Sacituzumab govitecan, an FDA-approved ADC targeting TROP2, has demonstrated substantial clinical efficacy in triple-negative breast cancer (TNBC). Meanwhile, B7-H3 is being explored for neuroblastoma and other pediatric cancers, offering a novel immunotherapy angle.
Another interesting target is CEACAM5, especially in colorectal and pancreatic cancers, and several early-stage trials are ongoing to assess its utility. With better target validation and advanced screening platforms, companies can now identify tumor-specific antigens with higher selectivity and lower toxicity.
The growing repertoire of targets is also helping diversify ADC pipelines. Biopharmaceutical companies are conducting extensive preclinical studies using multi-omics and single-cell RNA sequencing to discover and validate new antigens. Importantly, the success of emerging targets could lead to more personalized ADC therapies and enable treatment for rare cancers.
However, these advances come with challenges. Tumor heterogeneity, antigen shedding, and off-target expression must be addressed through advanced targeting strategies and conjugation chemistries. Moreover, companion diagnostics will play an essential role in identifying suitable patient populations for these new ADCs.
In summary, the focus on emerging targets beyond HER2 and CD30 is opening up promising treatment options, increasing competition among biopharma companies, and paving the way for next-generation ADCs. The continued evolution of ADC targets signifies not only an expansion in therapeutic scope but also a commitment to precision oncology.
